GlioCure receives the "Seal of Excellence" from the European Commission

GlioCure was awarded the "Seal of Excellence" under the H2020 Instrument PME phase 1 scheme for its project "Game-changing anti-mitotic peptide for the treatment/cure of glioblastoma and other aggressive cancers over-expressing βIII-tubulin".

The project was evaluated by a panel of international experts who gave it a score above the 13/15 threshold of excellence for the three criteria of scientific excellence, impact and quality and efficiency of implementation.